Tennessee Senate Bill SB1495

Tennessee 2025-2026 Regular Session

• Introduced: 12/23/25
• Engrossed: 2/19/26
• Enrolled: 4/20/26
• Passed: 5/5/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 20 and Title 33, relative to opioids.

Impact

If enacted, SB1495 would modify existing state laws related to the regulation of pharmaceuticals, particularly concerning the opioids market. By expanding the list of companies held liable for the opioid epidemic, the bill aims to create stricter accountability measures and enhance regulatory oversight. This change could have significant implications on how these companies conduct business in Tennessee, potentially leading to changes in their marketing practices and financial liabilities associated with wrongful actions in opioid promotion and distribution.

Summary

Senate Bill 1495 is an act aimed at amending Tennessee Code Annotated, specifically Title 20 and Title 33, in relation to opioids. The bill seeks to update the language regarding certain pharmaceutical companies involved in opioid production, specifically targeting Purdue Pharma L.P., Alvogen, Inc., Apotex Corp., and Zydus Pharmaceuticals (USA) Inc. This amendment reflects an attempt to hold accountable the companies that have played a significant role in the opioid crisis, which has severely impacted public health across the state.

Sentiment

The sentiment around SB1495 is expected to be largely supportive, especially among health advocacy groups and lawmakers who are concerned about the ongoing opioid crisis. Proponents generally view the bill as a necessary step toward improving public health outcomes and ensuring accountability from pharmaceutical companies. However, there may be some contention from parties who fear over-regulation could impact pharmaceutical availability and innovation.

Contention

Notable points of contention may arise regarding the implications of holding pharmaceutical companies accountable. Critics of expansive regulatory measures often caution that such actions might lead to negative consequences for consumers in terms of drug availability. Furthermore, there may be debate on whether the legislation effectively addresses the root causes of addiction or simply serves to penalize manufacturers without providing solutions for treatment and prevention.